cerrar
Tagged with Regulation,

The Case for an Algerian FDA in the Wake of Unethical TV Ads
In the wake of a spate of television advertisements for dietary supplements claiming to offer solutions to the COVID-19 crisis, regular…

Xavier De Cuyper – CEO, Belgian Federal Agency for…
Xavier De Cuyper introduces the Federal Agency for Medicines & Health Products (FAMHP) and the essential role it plays in Belgium’s healthcare…

A New Era of Access to Innovation in the Czech Republic?
Pharma industry stakeholders are generally quick to suggest that the Czech Republic is one of the most over-regulated markets in Europe, with new or…

New PMDA Head Yasuhiro Fujiwara Sets Out Top Priorities for…
In April 2019, Yasuhiro Fujiwara was appointed as the new chief executive of Japan’s drug regulator and one of the world’s foremost regulatory…

Barbara Lopez Kunz – CEO, Drug Information Association…
Barbara Lopez Kunz, CEO of the Drug Information Association (DIA) in the USA, outlines the association’s four key areas of focus – regulatory…

Mexican Healthcare Reforms: Question Marks Remain
The election of populist President Andres Manuel Lopez Obrador (AMLO) on 1 July 2018 heralded a new era of hope and optimism for Mexicans. In the…

Romania’s Emergency Healthcare Ordinance: Papering Over Larger…
State hospitals in Bucharest are increasingly overloaded with patients due to a lack of resources and specialists. This pressure is amplified by the…

Key Developments in Russian Pharma 2019
The year 2019, which continued the trend of rapid and numerous changes in healthcare regulations in Russia, was rich with expectations, events and…

The US in 2020: Structural Constraints to Rein in Political…
Eurasia Group’s Aditya Bhattacharji examines the stalling of healthcare reforms in the US and what changes to US healthcare it is realistic to…

Mátyás Szentiványi – Director General, National…
Dr Mátyás Szentiványi, Director General of the National Institute of Pharmacy and Nutrition (OGYEI), introduces the administrative authority and…

US FDA’s Efforts to Advance the Development of Gene Therapy
Peter Marks, director of the US FDA's Center for Biologics Evaluation and Research, outlines how the organization is attempting to further promote the…

ICER Strikes Again: Scandal Time?
The US drug-price watchdog, The Institute for Clinical & Economic Review (ICER) recently issued a “Report on Unsupported Price Increases“,…
We use cookies to ensure that we give you the best experience on our site. For more info

See our Cookie Privacy Policy Here